Leadership

Mr. Clark has more than 35 years of experience in the biotechnology and pharmaceutical industry, most recently serving as CEO and member of the board of directors for Genentech, until his retirement in 2016.

During his seven-year tenure as CEO, Ian and his team brought eleven new medicines to market for patients fighting rheumatoid arthritis, idiopathic pulmonary fibrosis and various types of cancer. Ian was among the highest rated CEOs by Glassdoor, recognized as the Bay Area’s most admired CEO by the San Francisco Business Times and awarded the Honorable Mentor of the Year by the Heath Business Woman's Association.

Prior to joining Genentech, Ian held various positions of increasing responsibility at Novartis, Sanofi, Ivax and Searle, working in the USA, UK, Canada, Eastern Europe and France.

Currently, Ian is on the board of directors for Takeda, Guardant Health, Olema Oncology and Kyverna Therapeutics.

Ian previously served on the Boards of Forty-Seven, Shire, Kite Pharma, Agios Pharmaceuticals, Dendreon, Solazyme and Vernalis. He was also on the Board of the Biotechnology Industry Association and on the Economic Advisory Council of the 12th District of the Federal Reserve and on the BioFulcrum Board of the Gladstone Institute.

Ian received his bachelor of science in Biological Sciences and an Honorary Doctorate of Science from Southampton University in the United Kingdom.

Mr. Gould is currently a Partner at Adams Street Partners, LLC, a global private equity firm, and has been employed by Adams Street Partners or its predecessor organizations since 1994. Mr. Gould currently serves on the boards of directors of several private biopharmaceutical and/or healthcare companies. Mr. Gould received an A.B. in Engineering Science from Dartmouth College and an M.B.A. from the Stanford University Graduate School of Business.

Dr. Grais was president and chief executive officer of Ocera Therapeutics, Inc., a biopharma company developing new treatments for serious liver disease, until its acquisition by Mallinckrodt. Prior to that, she was a partner at InterWest Partners, a venture capital firm focused on biotechnology and medical device companies. Previously, Dr. Grais was a founder and executive vice president of Structural GenomiX, Inc., a drug discovery company focusing on new treatments for cancer that was acquired by Eli Lilly & Co. Earlier in her career, she was a corporate attorney at Wilson Sonsini Goodrich & Rosati, where she represented life science companies in venture financings, public offerings and strategic partnerships. Before practicing law, Dr. Grais worked as an assistant professor in the Department of Internal Medicine at the University of California, San Francisco. Dr. Grais currently serves on the board of directors of Arca Biopharma, Inc., ICON plc and Collective Health, a private healthcare services company. Dr. Grais received a B.A. in philosophy from Yale University, an M.D. from Yale Medical School, and a J.D. from Stanford Law School.

Dr. Miller was co-founder and CEO of Pharmacyclics, where he led the initial discovery and development efforts for ibrutinib. Prior to that, he was a co-founder, Vice President and Director of IDEC (which merged to form Biogen IDEC, now Biogen), where he led research efforts on lymphoma culminating in the development of rituximab. He has also founded other private and public biotech companies. Dr. Miller received an M.D. from the State University of New York Medical School. He is a board-certified oncologist and is currently Adjunct Clinical Professor of Medicine (oncology) at Stanford University Medical Center.

Mr. Morrison was a Partner with Ernst & Young LLP from 1996 to December 2015, where he also served as U.S. Life Sciences Leader from 2002 through December 2015. Mr. Morrison has held roles on the boards of directors of numerous life sciences industry organizations. Mr. Morrison currently serves on the boards of directors of Tarsus Pharmaceuticals, Inc., Ideaya Biosciences, Inc., Zai Labs, Inc. and Vera Therapeutics, Inc. Since 1999, he has served on the board of directors of the Biotechnology Institute, a nonprofit organization, where he has served on the audit committee since 2002. Mr. Morrison previously served on the boards of directors of the Life Sciences Foundation, a biotechnology nonprofit organization, the Bay Area Biosciences Association, a 501(c)(3) organization, and the Emerging Companies Section of the Biotechnology Industry Organization (BIO), a trade organization.

Dr. Thompson is currently a Member at OrbiMed Advisors LLC and has over 20 years of industry experience. He co-founded and was CEO of Trubion Pharmaceuticals and serves as a director on the boards of several public and private companies. He previously held executive positions at Chiron Corporation and Becton Dickinson. Dr. Thompson is an Ernst & Young Entrepreneur of the Year awardee, an Affiliate Professor of Neurosurgery at the University of Washington, an inventor on numerous patents, and a board-certified internist and oncologist.